UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Lowers Holdings in OPKO Health, Inc. (NASDAQ:OPK)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its stake in shares of OPKO Health, Inc. (NASDAQ:OPK) by 19.8% in the third quarter, HoldingsChannel reports. The institutional investor owned 605,058 shares of the biotechnology company’s stock after selling 149,104 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in OPKO Health were worth $902,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Rubric Capital Management LP lifted its position in shares of OPKO Health by 9.6% in the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after buying an additional 4,284,336 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in OPKO Health by 142.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock worth $2,227,000 after acquiring an additional 876,272 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of OPKO Health during the 2nd quarter worth approximately $592,000. Y.D. More Investments Ltd bought a new position in shares of OPKO Health during the 2nd quarter valued at approximately $1,840,000. Finally, BNP Paribas Financial Markets boosted its position in shares of OPKO Health by 736.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock valued at $368,000 after acquiring an additional 217,450 shares during the last quarter. Institutional investors own 64.63% of the company’s stock.

Insider Transactions at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 125,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was purchased at an average cost of $1.59 per share, with a total value of $198,750.00. Following the purchase, the chief executive officer now owns 212,536,477 shares of the company’s stock, valued at approximately $337,932,998.43. The trade was a 0.06 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders bought 1,304,255 shares of company stock worth $2,024,605. 47.26% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on OPK shares. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research note on Thursday, September 26th. Barrington Research restated an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a report on Friday, November 8th. StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, Piper Sandler reissued an “overweight” rating and set a $3.00 price objective on shares of OPKO Health in a research note on Tuesday, September 17th.

OPKO Health Stock Up 0.6 %

Shares of OPK opened at $1.57 on Friday. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The business has a fifty day moving average of $1.54 and a 200 day moving average of $1.48. The company has a market cap of $1.07 billion, a PE ratio of -8.26 and a beta of 1.62. OPKO Health, Inc. has a 52-week low of $0.85 and a 52-week high of $1.76.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.